KRAS and acute lymphoblastic leukemia: Interestingly, the GRAALL study confirmed an interaction between MRD and oncogene expression, the risk of relapse being the highest for MRDpos patients with KMT2A positivity or IKZF1-deleted B-ALL, or with NOTCH1/FBW7WT and/or N/K-RAS-mutated and/or PTEN-altered T-ALL.36 Again, a subset analysis of the NILG trial restricted to patients with CD20+ B-ALL demonstrated that patients with this poor-risk ALL subset have an excellent outcome even without allo-SCT when MRD negativity is achieved.37